Genomic Health, Inc. today announced presentation of three studies at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, including one finding that high tumor grade was not a marker of higher recurrence risk in stage II colon cancer, suggesting that other markers, such as the Oncotype DX® Recurrence Score® (RS) test as well as T-stage and mismatch repair (MMR) status, should be considered by physicians during the treatment decision-making process.
More...
Hybrid Mode
